



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/941,682

08/30/2001

Christian Mayaud

47777-0009

9565

53437 7590 07/17/2008

ROBERT M. SCHWARTZ, P.A.

P.O. BOX 221470

HOLLYWOOD, FL 33022

EXAMINER

PORTER, RACHEL L

ART UNIT

PAPER NUMBER

3626

MAIL DATE

DELIVERY MODE

07/17/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 09/941,682	Applicant(s) MAYAUD, CHRISTIAN	
	Examiner RACHEL L. PORTER	Art Unit 3626	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 01 April 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 97-123 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 97-123 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Notice to Applicant

1. This communication is in response to the amendment filed 4/01/08. Claims 97-123 are pending.

Continued Examination Under 37 CFR 1.114

2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 4/1/08 has been entered.

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

4. Claims 119-120 rejected under 35 U.S.C. 102(b) as being anticipated by Renvall (WO 91/02447),
[Claim 119] Renvall discloses a method for aggregating electronic prescription data, comprising the steps of:

- electronically storing at least a first patient record including at least one prescribed drug selected from a list of drugs (approved by a drugs benefit provider) and a prescriber identifier representing the user that selected the at least one prescribed drug; (Figure 2, page 5, lines 21-27; pages 7, line 28-page 8, line 5)
- electronically storing at least a second patient record including at least one prescribed drug selected from a list of drugs (approved by a drugs benefit provider) and a prescriber identifier representing the user that selected the at least one prescribed drug; (pages 7, line 28-page 8, line 5-- The doctor makes his/her rounds with multiple patients scanning their health conditions, storing this information in a barcode reader.)
- aggregating data from the at least a first patient record with data from the at least a second data patient record to form an aggregated data record; and (pages 7, line 28-page 8, line 5-- The doctor makes his/her rounds with multiple patients scanning their health conditions, storing this information in a barcode reader.)
- outputting the aggregated data record. (pages 7, line 28-page 8, line 5--Then this information is also registered from the barcode device to a PC, also Rx's can be written)

It is noted that Claim 119 has been amended to recite that the patient record includes at least one prescribed drug "selected from a formulary list of drugs."

Furthermore, there is a recitation that "the formulary list is approved by a drug benefits provider."

As per these recitations, the limitations lie beyond the scope of the recited invention. In particular, the recited method does not include a step approving drugs, or selecting scanning or entering the medications from the compiled list of drugs. Thus, the manner of forming the drug list (i.e. approved by drug benefit provider) is not pertinent. It should be noted that only the components from the system which affect the resultant function of the system, or data in the method, which affects the outcome of the method will be given patentable weight and have art applied accordingly.

In particular, these limitations are nonfunctional description material and are not functionally involved in the steps recited. The steps recited in claim 119 (would be performed the same regardless of the data contents noted material (“selected from a formulary list of drugs”, “the formulary list is approved by a drug benefits provider.”) Thus, this descriptive material will not distinguish the claimed invention from the prior art in terms of patentability. See *In re Gulack*, 703 F.2d 1381, 1385, 217 USPQ 401, 404 (Fed. Cir. 1983); *In re Lowry*, 32F.3d 1579, 32 USPQ2d 1031 (Fed. Cir. 1994).

[Claim 120] Renvall discloses the method of claim 119, wherein:

- each of the at least a first patient record and the at least a second patient record additionally includes at least one patient condition associated with the at least one prescribed drug selected from a list and at least one prescriber identifier representing the user that selected the at least one prescribed drug; and (Figure 2; page 7, lines 28-page 8, line 5—medication of patient, state of health, name of doctor—all linked with one another)t

- the aggregated data record includes at least a selected drug, its associated patient condition and its associated prescriber identifier for each patient data record. pages 7, line 28-page 8, line 5-- The doctor makes his/her rounds with multiple patients scanning their health conditions, storing this information in a barcode reader.)

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

6. Claims 121-122 are rejected under 35 U.S.C. 103(a) as being unpatentable over Renvall.

[Claims 121-122] Renvall discloses the method of claim 119 as explained in the rejection of claim 119. Renvall further discloses providing a report (i.e. output) that includes the prescriber information/ identifier(Figure 2). Renvall does not expressly disclose sorting the aggregated report by particular parameters. However, at the time of the applicant's invention, it would have been obvious to one of ordinary skill in the art to modify the system and method of Renvall to provide aggregated reports which could be sorted by various parameters, including medication, patient name, date, and prescriber. One would have been motivated to include this feature to provide a system and method that is adaptable to the preferences and demands of the healthcare providers who use it.

7. Claim 123 is rejected under 35 U.S.C. 103(a) as being unpatentable over Renvall in view of Official Notice (as substantiated by "Big Brother-Is He Here?" –Anonymous) [Claim 123]] Renvall teaches the method of claim 119 as explained in the rejection of claim 119, but does not expressly disclose the step of selling information derived from the aggregated data. However, gathering customer and selling "lead" data is old and well known in the art. For example, the "Big Brother" reference discloses that "vast amounts of personal knowledge" were routinely collected and stored in private databanks (par. 6) and that "private organizations compiled records of drug testing; social science screening ...computerized medical records..." (par. 7-8) The reference further discusses "information vendors" and the collection of customer data to be used and sold to third parties and the customer's ability to opt out of such programs. (par. 11-13) At the time of the applicant's invention, it would have been obvious to one of ordinary skill in the art to modify the method of Renvall to take information derived from the aggregated records and sell this information (e.g. to pharmaceutical companies). One would have been motivated to include this feature to increase the marketability of the system and to help offset certain costs associated in setting up the system.

8. Claims 97-106 and 114-118 are rejected under 35 U.S.C. 103(a) as being unpatentable over Renvall (WO 91/02447) in view of Brown et al ("A computerized prescription writing Program for program for Doctors" and Doyle, Jr. (USPN 5,070,452) [Claim 97] Renvall discloses a computer-implemented method for assembling a prescription, the method comprising:

- providing an electronic database of drugs; (Renvall: page 5, line 37- page 6, line 15-alphanumeric designations are assigned to diagnoses, types of care...**medicines**. All bar codes and corresponding information are collected in catalogues and in the memory or computers of the information handling system. In each country a central database with all the barcodes and corresponding information is provided.)
- electronically storing a patient identifier in a computer memory medium; (pg. 7, line 28-pg. 8, line 5)
- electronically associating with the patient identifier a drug selected from a list of drugs; (Figure 2, page 5, lines 21-27) Claim 123 are rejected under 35 U.S.C. 103(a) as being unpatentable over Renvall in view of Official Notice (as substantiated by “Big Brother-Is He Here?” –Anonymous)/
- electronically associating a dosage for the selected drug, with the patient identifier and the selected drug; and (Figure 2: patient name and dosage)
- retrieving and outputting the associated selected drug and dosage associated with a patient identifier. (Fig. 2; page 7, lines 28-34, page 8, 27-34)

Claim 97 also further recites:

- electronically identifying from the database of drugs, a list of drugs approved by a drugs benefit provider for the patient associated with the patient identifier.

Renvall does not expressly disclose electronically identifying a list of drugs from the drug database. Brown discloses electronically identifying a list of drugs/ subset of drugs

Art Unit: 3626

from a drug database. (pg. 101: par. 1-3; pg. 102, par. 7) At the time of the Applicant's invention, it would have been obvious to one of ordinary skill in the art to electronically identify a subset or list of drugs from a drug database when providing a prescription. As suggested by Brown, one would have been motivated to include this feature to speed the prescription writing process, accessing a personal drug formulary which is appropriately indexed. (page 101: summary, par. 3; page 19, par. 18)

Renvall and Brown do not expressly disclose that the list of drug is approved by a drugs benefits provider. However, it is well-known to electronically notify healthcare providers whether particular treatments are approved by a healthcare benefit provider for a patient associated with a patient identifier, as evidenced by Doyle. (col. 2, lines 45-56; col. 4, line 54-62; col. 5, lines 56-64). At the time of the applicant's invention, it would have been obvious to one of ordinary skill in the art to combine the teachings of Doyle with the method of Renvall in view of Brown to electronically identify a list of treatments (e.g. drugs) that are approved by a benefits provider for a patient associated with the patient identifier. As suggested by Doyle, one would have been motivated to include this feature to facilitate the claims adjudication process for the health care provider and payer. (col. 2, lines 4-25)

Claim 97 has been amended to recite:

- electronically associating the patient identifier with a drug benefits provider or insurance company for a patient associated with the patient identifier;

- electronically accessing a formulary associated with the drug benefits provider or insurance company for a patient associated with the patient identifier.

Renvall does not expressly disclose electronically associating the patient identifier with a drug benefits provider or insurance company for a patient associated with the patient identifier and electronically accessing a formulary associated with the drug benefits provider or insurance company for a patient associated with the patient identifier. Brown discloses electronically identifying a list of drugs/ subset of drugs from a drug database. (pg. 101: par. 1-3; pg. 102, par. 7) Brown further discloses electronically associating a patient identifier with drugs in a formulary list (pgs. 102-103, par. 7-11) At the time of the Applicant's invention, it would have been obvious to one of ordinary skill in the art to combine to method of Renvall with the teaching of Brown for the reasons previously described.

Renvall and Brown do not expressly disclose that the list of drug is approved by a drugs benefits provider. Renvall and Brown also do not disclose electronically accessing a formulary associated with the drug benefits provider or insurance company for a patient associated with the patient identifier

However, it is well-known to electronically notify healthcare providers whether particular treatments are approved by a healthcare benefit provider for a patient associated with a patient identifier, as evidenced by Doyle. (col. 2, lines 45-56; col. 4, line 54-62; col. 5, lines 56-64). At the time of the applicant's invention, it would have been obvious to one of ordinary skill in the art to combine the teachings of Doyle with the method of Renvall in view of Brown to include the steps of electronically associating

Art Unit: 3626

the patient identifier with a drug benefits provider or insurance company for a patient associated with the patient identifier and electronically accessing treatments associated with the drug benefits provider or insurance company for a patient associated with the patient identifier. As suggested by Doyle, one would have been motivated to include this feature to facilitate the claims adjudication process for the health care provider and payer. (col. 2, lines 4-25)

[Claim 98] Renvall discloses the method of claim 97, additionally comprising a patient condition, converted to electronic data and electronically identified by the patient identifier, the selected drug being chosen based on the patient condition. (page 7, lines 28-34: Doctor scans patient's state of health, then generates prescription with treatment/ with medication)

[Claim 99] Renvall discloses the method of claim 97, further including the steps of: aggregating at least a portion of the assembled prescription data associated with multiple patient identifiers; and storing the aggregated prescription data. (pages 7, line 28-page 8, line 5)

[Claim 100] Renvall discloses the method of claim 98, further including the steps of: electronically associating with each drug selected from a list and with the patient condition for which the drug was selected, a prescriber identifier representing the user that selected the drug; and (pages 7, line 28-page 8, line 5)

Art Unit: 3626

aggregating data records for multiple patient identifiers, each data record including at least a selected drug, its associated patient condition and the associated prescriber identifier. (pages 7, line 28-page 8, line 5)

The doctor makes his/her rounds with multiple patients scanning their health conditions, storing this information in a barcode reader. Then this information is also registered in a PC.

[Claim 101] Renvall discloses a method for assembling an electronic prescription, comprising the steps of:

- providing an electronic database of drugs; (Renvall: page 5, line 37- page 6, line 15-alphanumeric designations are assigned to diagnoses, types of care...medicines. All bar codes and corresponding information are collected in catalogues and in the memory or computers of the information handling system. In each country a central database with all the barcodes and corresponding information is provided.)
- electronically obtaining a patient identifier converted to electronic data; (page 7, lines 28-31, human and barcode format)
- electronically retrieving a dosage for the at least one prescribed drug associated with the at least one prescribed drug and the patient identifier; (page 7, lines 31-35—information registered with state of health and medication, and patient personal identifier data)

- storing the at least one prescribed drug, the dosage and the patient identifier in an electronic memory; and (page 7, lines 31-35: registered with state of health and medication, and patient personal identifier data)
- outputting at least the at least one prescribed drug. (Figure 2; page 8, line 31- page 9, line 3)

Claim 101 further recites:

- electronically retrieving from the database of drugs a list of drugs approved by a drugs benefit provider for the patient associated with the patient identifier, and the identity of at least one prescribed drug associated with the patient identifier, the at least one prescribed drug being selected from a list of drugs approved by a drugs benefit provider

Renvall discloses a method comprising electronically retrieving the identity of at least one prescribed drug associated with the patient identifier, the at least one prescribed drug being selected from a list of drugs; (Figure 2, page 5, lines 21-27; page 7, lines 31-35; page 9, lines 1-3)

Renvall does not expressly disclose electronically retrieving a list of drugs from a drug database. Brown discloses electronically retrieving a list of drugs/subset of drugs from a drug database. (pg. 101: par. 1-3; pg. 102, par. 7) At the time of the Applicant's invention, it would have been obvious to one of ordinary skill in the art to electronically identify and retrieve a subset or list of drugs from a drug database when providing a prescription. As suggested by Brown, one would have been motivated to include this

feature to speed the prescription writing process, accessing a personal drug formulary which is appropriately indexed. (page 101: summary, par. 3; page 19, par. 18)

Renvall and Brown do not expressly disclose that the list of drug is approved by a drugs benefits provider. However, it is well-known to electronically notify healthcare providers whether particular treatments are approved by a healthcare benefit provider for a patient associated with a patient identifier, as evidenced by Doyle. (col. 2, lines 45-56; col. 4, line 54-62; col. 5, lines 56-64). At the time of the applicant's invention, it would have been obvious to one of ordinary skill in the art to combine the teachings of Doyle with the method of Renvall in view of Brown to electronically identify a list of treatments (e.g. drugs) that are approved by a benefits provider for a patient associated with the patient identifier. As suggested by Doyle, one would have been motivated to include this feature to facilitate the claims adjudication process for the health care provider and payer. (col. 2, lines 4-25)

Claim 101 also further recites:

- electronically identifying from the database of drugs, a list of drugs approved by a drugs benefit provider for the patient associated with the patient identifier.

Renvall does not expressly disclose electronically identifying a list of drugs from the drug database. Brown discloses electronically identifying a list of drugs/ subset of drugs from a drug database. (pg. 101: par. 1-3; pg. 102, par. 7) At the time of the Applicant's invention, it would have been obvious to one of ordinary skill in the art to electronically identify a subset or list of drugs from a drug database when providing a prescription. As

suggested by Brown, one would have been motivated to include this feature to speed the prescription writing process, accessing a personal drug formulary which is appropriately indexed. (page 101: summary, par. 3; page 19, par. 18)

Renvall and Brown do not expressly disclose that the list of drug is approved by a drugs benefits provider. However, it is well-known to electronically notify healthcare providers whether particular treatments are approved by a healthcare benefit provider for a patient associated with a patient identifier, as evidenced by Doyle. (col. 2, lines 45-56; col. 4, line 54-62; col. 5, lines 56-64). At the time of the applicant's invention, it would have been obvious to one of ordinary skill in the art to combine the teachings of Doyle with the method of Renvall in view of Brown to electronically identify a list of treatments (e.g. drugs) that are approved by a benefits provider for a patient associated with the patient identifier. As suggested by Doyle, one would have been motivated to include this feature to facilitate the claims adjudication process for the health care provider and payer. (col. 2, lines 4-25)

Claim 101 has been amended to recite:

- electronically associating the patient identifier with a drug benefits provider or insurance company for a patient associated with the patient identifier;
- electronically accessing a formulary associated with the drug benefits provider or insurance company for a patient associated with the patient identifier.

Renvall does not expressly disclose electronically associating the patient identifier with a drug benefits provider or insurance company for a patient associated

with the patient identifier and electronically accessing a formulary associated with the drug benefits provider or insurance company for a patient associated with the patient identifier. Brown discloses electronically identifying a list of drugs/ subset of drugs from a drug database. (pg. 101: par. 1-3; pg. 102, par. 7) Brown further discloses electronically associating a patient identifier with drugs in a formulary list (pgs. 102-103, par. 7-11) At the time of the Applicant's invention, it would have been obvious to one of ordinary skill in the art to combine to method of Renvall with the teaching of Brown for the reasons previously described.

Renvall and Brown do not expressly disclose that the list of drug is approved by a drugs benefits provider. Renvall and Brown also do not disclose electronically accessing a formulary associated with the drug benefits provider or insurance company for a patient associated with the patient identifier

However, it is well-known to electronically notify healthcare providers whether particular treatments are approved by a healthcare benefit provider for a patient associated with a patient identifier, as evidenced by Doyle. (col. 2, lines 45-56; col. 4, line 54-62; col. 5, lines 56-64). At the time of the applicant's invention, it would have been obvious to one of ordinary skill in the art to combine the teachings of Doyle with the method of Renvall in view of Brown to include the steps of electronically associating the patient identifier with a drug benefits provider or insurance company for a patient associated with the patient identifier and electronically accessing treatments associated with the drug benefits provider or insurance company for a patient associated with the patient identifier. As suggested by Doyle, one would have been motivated to include

this feature to facilitate the claims adjudication process for the health care provider and payer. (col. 2, lines 4-25)

[Claims 102-105] Renvall discloses the method of claim 101, further including the step of electronically associating a patient condition, converted to electronic data with the patient identifier, the prescribed drug being selected based on the patient condition. (page 7, lines 28-34). The patient's history record includes prescribed drug and dosage information (Figure 2) and patient condition (i.e. state of health).

[Claim 106] Renvall discloses a method further comprises storing patient data in an electronic memory, as explained in the rejection claim 101. Renvall further discloses that the memory is part of a source-oriented data-retrieval subsystem, the data retrieval subsystem being connectable to access at least one data-retrieval network to retrieve source prescribing information and patient-related data to the point-of-care from at least one remote source database. (page 7, lines 2-4; 28-page 8, line 5; col. 10, lines 20-25—networking)

[Claims 114-116] Renvall discloses a system and method further including the steps of defining a prescription expiration routine including dosing, amount and expiration drug quantifiers and including system calculation of a relationship between the drug quantifiers. (Figure 2); selectively storing the electronic prescription in local storage, in remote storage and in remote file transfer (page 8, lines 21-33); and further including

the step of transmitting the electronic prescription across a network for fulfillment by a specified pharmacy. (page 8, lines 31-33).

[Claim 117] Renvall discloses the method of claim 101, further including the steps of: aggregating at least a portion of the assembled prescription data associated with multiple patient identifiers; (Figure 2; page 7, lines 28-page 8, line 5) and storing the aggregated prescription data. (page 7, lines 34 -page 8, line 5)

[Claim 118] Renvall discloses the method of claim 101, further including the steps of:

- electronically associating with each drug selected from a list and with the patient condition for which the drug was selected, a prescriber identifier representing the user that selected the drug; and (Figure 2; page 7, lines 28-page 8, line 5— medication of patient, state of health, name of doctor—all associated with one another)
- aggregating data records for multiple patient-identifiers, each data record including at least a selected drug, its associated patient condition and the associated prescriber identifier.(page 7, lines 34 -page 8, line 5)

9. Claim 107 rejected under 35 U.S.C. 103(a) as being unpatentable over Renvall, Brown, and Doyle, as applied to claim 101 and in further view of Howson (USPN 5,088,981)

[Claim 107] Renvall teaches the method of claim 101, but does not expressly disclose electronically associating the patient record with allergies or drug interactions. Howson

Art Unit: 3626

discloses a system/method wherein the patient information is electronically associated with drug interaction information/allergies. (col. 7, lines 5-30; col. 16, lines 36-40) The system method is equipped to look up drug dosage/proper prescription information, check for drug interactions and update the patient's records accordingly. At the time of the invention, it would have been obvious to one of ordinary skill in the art to modify the system/method of Renvall with the teaching of how to include information on drug interactions or allergies. One would have been motivated to include this feature to include information to ensure the safety and health of the patient receiving the prescription. (Howson: col. 1, lines 17-21)

10. Claims 108-112 rejected under 35 U.S.C. 103(a) as being unpatentable over Renvall, Brown and Doyle, as applied to claims 101 and 103 and in further view of "Data Hard to Get, Has Many Applications" (Anonymous).

[Claims 108-110] Renvall, Brown, and Doyle disclose a method for assembling an electronic prescription as explained in the rejection of claim 101. Renvall further discloses displaying the patient record (page 8, lines 22-24), but does not expressly disclose assembling the patient records from multiple databases, and issuing a drug benefit plan with preferred drug formularies to the patient. "Data Hard to Get..." discloses a system and method wherein patient data and drug formulary data is assembled from a plurality of sources/databases (page 4, par. 22-25) and wherein drug formulary data, including preferred drugs for a condition are provided (par. 24-25). At the time of the Applicant's invention it would have been obvious to one of ordinary skill

in the art to modify the system/method of Renvall with the teaching of “Data Hard to Get...”. As suggested by the article, one would have been motivated to include these features to facilitate benefits management and to ascertain the appropriateness of a treatment. (par. 25).

[Claim 111] Renvall, Brown, and Doyle disclose a method for assembling an electronic prescription as explained in the rejection of claim 101. Renvall further discloses a system and method for accessing patient drug information, (page 7, lines 28-34), and patient drug selection(page 8, lines 22-27) but does not disclose accessing remote database get formulary information. “Data Hard to Get...” discloses a system and method wherein patient data and drug formulary data is assembled from a plurality of sources/databases (page 4, par. 22-25) and wherein drug formulary data, including preferred drugs for a condition are provided (par. 24-25). At the time of the Applicant’s invention it would have been obvious to one of ordinary skill in the art to modify the system/method of Renvall with the teaching of “Data Hard to Get...”. As suggested by the article, one would have been motivated to include these features to facilitate benefits management and to ascertain the appropriateness of a treatment. (par. 25).

[Claim 112] Renvall discloses the method of claim 101 as explained in the rejection of claim 101, but does not describe providing information on formulary guidelines. “Data Hard to Get...” discloses a system and method wherein patient data and drug formulary data is provided from a plurality of sources/databases (page 4, par. 22-25) and wherein

drug formulary data, including preferred drugs for a condition are provided (par. 24-25).

At the time of the Applicant's invention it would have been obvious to one of ordinary skill in the art to modify the system/method of Renvall with the teaching of "Data Hard to Get...". As suggested by the article, one would have been motivated to include these features to facilitate benefits management and to ascertain the appropriateness of a treatment. (par. 25).

11. Claims 113 is rejected under 35 U.S.C. 103(a) as being unpatentable over Renvall, Brown, and Doyle and in further view of Official Notice (as substantiated by Howson-US 5,070,452)

[Claim 113] Renvall teaches the method of claim 101 as explained in the rejection of claim 101, but does not expressly disclose logging information regarding 3rd party access. Renvall does disclose protecting patient data (page 8, lines 3-5). Moreover, the use of audit trails for data access is well known in the art. For example, Howson discloses information regarding patient treatment time, date is gathered for audit trail purposes. Furthermore, any access to the patient's record must be signed off on and is made a permanent part of that patient's record. (col. 16, lines 6-46) At the time of the Applicant's invention, it would have been obvious to one of ordinary skill in the art to modify the system/method of Renvall to include an audit trail feature, with the motivation of ensuring patient information is closely monitored (page 9, lines 27-30)

Response to Arguments

12. Applicant's arguments with respect to the arguments submitted 4/1/08 have been considered but are moot in view of the new ground(s) of rejection. The examiner has provided additional citations and explanations in the rejection to address applicant's amendments.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to RACHEL L. PORTER whose telephone number is (571)272-6775. The examiner can normally be reached on M-F, 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, (Christopher) Luke Gilligan can be reached on (571) 272-6770. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3626

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/R. L. P./
Examiner, Art Unit 3626

/C Luke Gilligan/
Supervisory Patent Examiner, Art Unit 3626